ANIK
ANIK
NASDAQ · Biotechnology

Anika Therapeutics Inc

$14.63
-0.38 (-2.53%)
As of Jun 30, 10:28 PM ET ·
Financial Highlights (FY 2026)
Revenue
104.41M
Net Income
-10,069,561
Gross Margin
56.6%
Profit Margin
-9.6%
Rev Growth
-10.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 104.41M 116.37M 23.45M 26.68M
Gross Profit 59.06M 65.82M 6.64M 7.56M
Operating Income -10,232,309 -10,264,242 6.55M 7.58M
Net Income -10,069,561 -10,100,986 5.38M 7.18M
Gross Margin 56.6% 56.6% 28.3% 28.3%
Operating Margin -9.8% -8.8% 27.9% 28.4%
Profit Margin -9.6% -9.2% 22.9% 26.9%
Rev Growth -10.3% -10.3% -4.1% +21.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 38.69M 41.86M
Total Equity 99.18M 96.99M
D/E Ratio 0.39 0.43
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -5,256,396 -5,565,733 8.65M 11.22M
Free Cash Flow 4.59M 6.09M